Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (stat3) pathway: Inhibition of constitutive and interleukin 6-induced activation by iron depletion

Molecular Pharmacology

Volumn 87, Issue 3, 2015, Pages 543-560

  Lui, Goldie Y L ^a   Kovacevic, Zaklina ^a   Menezes, Sharleen V ^a   Kalinowski, Danuta S ^a   Merlot, Angelica M ^a   Sahni, Sumit ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; DEFEROXAMINE; DI 2 PYRIDELKETONE 4 CYCLOHEXYL 4 METHYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; INTERLEUKIN 6; MYC PROTEIN; PROTEIN BCL 2; STAT3 PROTEIN; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; IL6 PROTEIN, HUMAN; IRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL HETEROGENEITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IRON CHELATION; IRON DEPLETION; IRON METABOLISM; MALE; METASTASIS; MOUSE; NATIVE POLYACRYLAMIDE GEL ELECTROPHORESIS; NONHUMAN; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; PHYSIOLOGY; PROCEDURES; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; INTERLEUKIN-6; IRON; MALE; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THIOSEMICARBAZONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925283220     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.096529     Document Type: Article

References (87)

1. Assinder SJ, Dong Q, Kovacevic Z, and Richardson DR (2009) The TGF-beta, PI3K/Akt and PTEN pathways: Established and proposed biochemical integration in prostate cancer. Biochem J 417:411-421.
2. Bowman T, Garcia R, Turkson J, and Jove R (2000) STATs in oncogenesis. Oncogene 19:2474-2488.
3. Brasher BB and Van Etten RA (2000) c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 275:35631-35637.
4. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, and Darnell JE Jr (1999) Stat3 as an oncogene. Cell 98:295-303.
5. Cardoso AA, Jiang Y, Luo M, Reed AM, Shahda S, He Y, Maitra A, Kelley MR, and Fishel ML (2012) APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual- Targeting effectively inhibits pancreatic cancer cell survival. PLoS ONE 7:e47462.
6. Chao J, Synold TW, Morgan RJ Jr, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, and Stoller RG et al. (2012) A phase I and pharmacokinetic study of oral 3- Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: A California Cancer Consortium Study. Cancer Chemother Pharmacol 69:835-843.
7. Chen Z, Zhang D, Yue F, Zheng M, Kovacevic Z, and Richardson DR (2012) The iron chelators Dp44mT and DFO inhibit TGF-b-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem 287:17016-17028.
8. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, Ackland L, and Ahmed N (2009) Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 100:134-144.
9. Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, and Bardeesy N (2011) STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71:5020-5029.
10. Darnell G and Richardson DR (1999) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation. Blood 94:781-792.
11. Darnell JE Jr (1997) STATs and gene regulation. Science 277:1630-1635.
12. Darnell JE Jr, Kerr IM, and Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
13. Dixon KM, Lui GY, Kovacevic Z, Zhang D, Yao M, Chen Z, Dong Q, Assinder SJ, and Richardson DR (2013) Dp44mT targets the AKT, TGF-b and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. Br J Cancer 108:409-419.
14. Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM, and Ihle JN (1997) Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 17:2497-2501.
15. Fu D and Richardson DR (2007) Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 110:752-761.
16. Gao J and Richardson DR (2001) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 98:842-850.
17. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, and Brodeur GM et al. (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124.
18. Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, and Huang S (2005) Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11:1386-1393.
19. Gutierrez E, Richardson DR, and Jansson PJ (2014) The anticancer agent di-2- pyridylketone 4, 4-dimethyl-3- Thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity. J Biol Chem 289:33568-33589.
20. Hahm ER and Singh SV (2010) Sulforaphane inhibits constitutive and interleukin-6- induced activation of signal transducer and activator of transcription 3 in prostate cancer cells. Cancer Prev Res (Phila) 3:484-494.
21. Haura EB, Turkson J, and Jove R (2005) Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2:315-324.
22. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, and Xin H et al. (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16:487-497.
23. Hunter T (1987) A tail of two src's: mutatis mutandis. Cell 49:1-4.
24. Ihle JN (1995) Cytokine receptor signalling. Nature 377:591-594.
25. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, and Tsao S et al. (2013) Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 19:1773-1783.
26. Jain N, Zhang T, Fong SL, Lim CP, and Cao X (1998) Repression of Stat3 activity by activation of mitogen- Activated protein kinase (MAPK). Oncogene 17:3157-3167.
27. Jayakumar S, Kunwar A, Sandur SK, Pandey BN, and Chaubey RC (2014) Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: Role of reactive oxygen species, GSH and Nrf2 in radiosensitivity. Biochim Biophys Acta 1840:485-494.
28. Jing N and Tweardy DJ (2005) Targeting Stat3 in cancer therapy. Anticancer Drugs 16:601-607.
29. Kalinowski DS and Richardson DR (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57:547-583.
30. Kamran MZ, Patil P, and Gude RP (2013) Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int 2013:421821.
31. Kovacevic Z, Chikhani S, Lovejoy DB, and Richardson DR (2011) Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: A new strategy for the treatment of pancreatic cancer. Mol Pharmacol 80:598-609.
32. Kovacevic Z, Chikhani S, Lui GY, Sivagurunathan S, and Richardson DR (2013) The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid Redox Signal 18:874-887.
33. Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth M, and Sexl V (2006) STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 10:77-87.
34. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, and Reed JC (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148:1567-1576.
35. Kulp KS, Green SL, and Vulliet PR (1996) Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDAMB- 453 human breast cancer cells. Exp Cell Res 229:60-68.
36. Le NT and Richardson DR (2004) Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: A link between iron metabolism and proliferation. Blood 104:2967-2975.
37. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, and McCubrey JA (2008) Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 7:1745-1762.
38. Lewis HD, Winter A, Murphy TF, Tripathi S, Pandey VN, and Barton BE (2008) STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 59 and 39 ends. Mol Cancer Ther 7:1543-1550.
39. Li L, Cheung SH, Evans EL, and Shaw PE (2010) Modulation of gene expression and tumor cell growth by redox modification of STAT3. Cancer Res 70:8222-8232.
40. Li Z, Tanaka H, Galiano F, and Glass J (2011) Anticancer activity of the iron facilitator LS081. J Exp Clin Cancer Res 30:34.
41. Lian JP, Word B, Taylor S, Hammons GJ, and Lyn-Cook BD (2004) Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: Effects of indole-3-carbinol (I3C) and genistein. Anticancer Res 24:133-137.
42. Liu W, Xing F, Iiizumi-Gairani M, Okuda H, Watabe M, Pai SK, Pandey PR, Hirota S, Kobayashi A, and Mo YY et al. (2012) N-myc downstream regulated gene 1 modulates Wnt-b-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med 4:93-108.
43. Lovejoy DB, Jansson PJ, Brunk UT, Wong J, Ponka P, and Richardson DR (2011) Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox- Active copper complex that accumulates in lysosomes. Cancer Res 71: 5871-5880.
44. Lovejoy DB, Sharp DM, Seebacher N, Obeidy P, Prichard T, Stefani C, Basha MT, Sharpe PC, Jansson PJ, and Kalinowski DS et al. (2012) Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J Med Chem 55:7230-7244.
45. Mamoon NM, Smith JK, Chatti K, Lee S, Kundrapu K, and Duhé RJ (2007) Multiple cysteine residues are implicated in Janus kinase 2-mediated catalysis. Biochemistry 46:14810-14818.
46. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, and Maruyama R et al. (2011) The JAK2/STAT3 signaling pathway is required for growth of CD441CD242 stem celllike breast cancer cells in human tumors. J Clin Invest 121:2723-2735.
47. Merlot AM, Kalinowski DS, and Richardson DR (2013a) Novel chelators for cancer treatment: Where are we now? Antioxid Redox Signal 18:973-1006.
48. Merlot AM, Pantarat N, Menezes SV, Sahni S, Richardson DR, and Kalinowski DS (2013b) Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanism. Mol Pharmacol 84:911-24.
49. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, and Cantor A et al. (2002) Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62:6659-6666.
50. Noulsri E, Richardson DR, Lerdwana S, Fucharoen S, Yamagishi T, Kalinowski DS, and Pattanapanyasat K (2009) Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am J Hematol 84:170-176.
51. Nurtjahja-Tjendraputra E, Fu D, Phang JM, and Richardson DR (2007) Iron chelation regulates cyclin D1 expression via the proteasome: A link to iron deficiencymediated growth suppression. Blood 109:4045-4054.
52. Richardson D, Ponka P, and Baker E (1994) The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res 54:685-689.
53. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, and Bernhardt PV (2006) Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem 49:6510-6521.
54. Richardson DR, Tran EH, and Ponka P (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295-4306.
55. Sahni S, Bae DH, Lane DJ, Kovacevic Z, Kalinowski DS, Jansson PJ, and Richardson DR (2014) The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells. J Biol Chem 289: 9692-9709.
56. Sansone P and Bromberg J (2012) Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30:1005-1014.
57. Sasse J, Hemmann U, Schwartz C, Schniertshauer U, Heesel B, Landgraf C, Schneider-Mergener J, Heinrich PC, and Horn F (1997) Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol Cell Biol 17: 4677-4686.
58. Schafer FQ and Buettner GR (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30:1191-1212.
59. Schneider CA, Rasband WS, and Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671-675.
60. Scholz A, Heinze S, Detjen KM, Peters M, Welzel M, Hauff P, Schirner M, Wiedenmann B, and Rosewicz S (2003) Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 125:891-905.
61. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, and Kwon BM (2009) Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 69:193-202.
62. Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G, and Bishayee A (2014) Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta 1845:136-154.
63. Srinivasan D, Sims JT, and Plattner R (2008) Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 27:1095-1105.
64. Sun J, Zhang D, Zheng Y, Zhao Q, Zheng M, Kovacevic Z, and Richardson DR (2013) Targeting the metastasis suppressor, NDRG1, using novel iron chelators: Regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway. Mol Pharmacol 83:454-469.
65. Sun Y, Yang S, Sun N, and Chen J (2014) Differential expression of STAT1 and p21 proteins predicts pancreatic cancer progression and prognosis. Pancreas 43:619- 623.
66. Tan FH, Putoczki TL, Stylli SS, and Luwor RB (2014) The role of STAT3 signaling in mediating tumor resistance to cancer therapy. Curr Drug Targets 15:1341-1353.
67. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, and Xie WD et al. (2009) Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 69:5876-5884.
68. Tuominen VJ, Ruotoistenmäki S, Viitanen A, Jumppanen M, and Isola J (2010) ImmunoRatio: A publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 12:R56.
69. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, and Jove R (1998) Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18:2545-2552.
70. Turkson J and Jove R (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19:6613-6626.
71. Venkatasubbarao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, Nawrocki ST, and Freeman JW (2013) Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Mol Cancer 12:104.
72. Vincent A, Herman J, Schulick R, Hruban RH, and Goggins M (2011) Pancreatic cancer. Lancet 378:607-620.
73. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, and Sznol M (2004) Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3- Aminopyridine- 2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 22:1553-1563.
74. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, and Coppola D et al. (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48-54.
75. Wang X, Crowe PJ, Goldstein D, and Yang JL (2012) STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int J Oncol 41:1181-1191.
76. Watts RN and Richardson DR (2001) Nitrogen monoxide (NO) and glucose: unexpected links between energy metabolism and no-mediated iron mobilization from cells. J Biol Chem 276:4724-4732.
77. Whitnall M, Howard J, Ponka P, and Richardson DR (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 103:14901-14906.
78. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, and Huang S (2004) Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23:3550-3560.
79. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX, and Fang JY (2008) Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 10:287-297.
80. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, and Jove R (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269:81-83.
81. Yu Y and Richardson DR (2011) Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1- Thioredoxin, and activation of ASK1. J Biol Chem 286:15413-15427.
82. Yu Y, Suryo Rahmanto Y, Hawkins CL, and Richardson DR (2011) The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4, 4-dimethyl-3- Thiosemicarbazone and 2-benzoylpyridine-4, 4-dimethyl-3- Thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity. Mol Pharmacol 79:921-931.
83. Yuan J, Lovejoy DB, and Richardson DR (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104:1450-1458.
84. Zhang X, Yin P, Di D, Luo G, Zheng L, Wei J, Zhang J, Shi Y, Zhang J, and Xu N (2009) IL-6 regulates MMP-10 expression via JAK2/STAT3 signaling pathway in a human lung adenocarcinoma cell line. Anticancer Res 29:4497-4501.
85. Zhao S, Venkatasubbarao K, Lazor JW, Sperry J, Jin C, Cao L, and Freeman JW (2008) Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 68:4221-4228.
86. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, and Simons JW (1999) Overexpression of hypoxiainducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830-5835.
87. Zushi S, Shinomura Y, Kiyohara T, Miyazaki Y, Kondo S, Sugimachi M, Higashimoto Y, Kanayama S, and Matsuzawa Y (1998) STAT3 mediates the survival signal in oncogenic ras- Transfected intestinal epithelial cells. Int J Cancer 78:326-330.